Patheon Launches Quick To Clinic(SM) Program

Patheon Launches Quick To Clinic(SM) Program: Goal Is To Reduce Development Time for Customers
     

    TORONTO, Nov. 12 /CNW/ - Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, will launch its recently enhanced Quick To Clinic(SM) program at the 2008 AAPS Annual Conference in Atlanta, Georgia.
    Patheon has refined its Quick to Clinic(SM) program, established earlier this year with the objective of accelerating drug development timelines for
customers. It has the dual advantage of accelerating stage-and-gate decision making and improving drug product delivery to the clinics, which in turn
improves time to market and reduces costs.
    The Quick to Clinic(SM) program is designed for rapid distribution of clinical trial materials for First Time in Human (Phase I) studies. Utilizing
Patheon's Milton Park (UK) and Whitby (Canada) facilities the Quick to Clinic(SM) program assures delivery of finished drug product within four
months from receipt of API. These designated delivery centers, specifically designed for early phase development, will provide responsive and flexible service to our customers who are under pressure to screen product ideas and make proof of concept decisions quickly
    Wes Wheeler, Patheon's CEO stated, "The Quick to Clinic(SM) program is another in a series of new innovative service offerings for our more than 300 development clients. Patheon is committed to development and commercialization of more than 40 different drug product formulations and will continue to offer its customers a wide range of services from its global network of laboratory, pilot plant and manufacturing facilities.

    ABOUT PATHEON

    Patheon Inc. (TSX: PTI; www.patheon.com <http://www.patheon.com> ) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(SM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon's integrated network strives to ensure that customer products can be launched with confidence
globally.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com <http://www.patheon.com>  or on SEDAR at www.sedar.com <http://www.sedar.com> .